Fish Vaccine Market Scope
Immunization of fish is often used for many years and is widely recognised as an efficient technique of preventing a variety of bacterial and viral infections. Vaccination initiatives contribute to global aquaculture's environmental, social, and economic sustainability. Traditionally, most licensed fish vaccines were inactivated microorganisms prepared with adjuvants and administered via immersion or injection. Subunit or recombinant DNA/RNA particle vaccines are examples of vaccinations made using modern vaccine technologies that target individual pathogen components. These cutting-edge technologies have been developed all around the world, and they appear to produce higher levels of immunity than traditional fish vaccines. Advanced technologies have showed significant promise for the future of aquaculture vaccines, and will give producers with health benefits as well as increased commercial potential.
The Fish Vaccine market study is segmented by Type (Live, Inactivated, Subunit, DNA and Others) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Fish Vaccine market throughout the predicted period.
AquaTactics Fish Health (United States), Hipra (India), Ictyogroup (France), Intervet International B.V. (Netherlands), Microsynbiotix (Ireland), Nisseiken Co., Ltd. (Japan), Pfizer Inc. (United States), Kyoritsuseiyaku Corporation (Japan) and Tecnovax S.A. (Argentina) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Veterquimica SA (Chile), Zoetis Inc. (United States), Merck KGaA (Germany) and Seppic (France).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AMA Research has segmented the market of Global Fish Vaccine market by Type, Application and Region.
On the basis of geography, the market of Fish Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
On 6th December, 2018 - Aquaculture Acquired Assets of KoVax Ltd. (Israel based Vaccine Manufacturer). Phibro's Position in Fish Vaccine Discovery Is Strengthened, And Its Aquaculture Product Line Is Expanded. The R&D Team from KoVax Joined Phibro's Biological Segment, With the Goal of Developing a Pipeline of Novel Vaccines for The Aquaculture. and On 25th January, 2017 – Pharmaq (Zoetis Unit) Acquired Norwegian Fish Vaccination Company. Pharmaq Will Be Able to Provide Complete Vaccination Solutions to Customers All Over the World as A Result of Its Takeover of Nordland Sett Vaks.
On 30th April, 2021 - CIBA Launched India's First Homegrown Fish Vaccine for Viral Nervous Necrosis (VNN). CIBA-Nodavac-R is an Injectable Recombinant VNN Vaccine That Efficiently Protects Fingerlings from VNN Produced by Red-Spotted Grouper Nervous Necrosis Virus (RGNNV) And Prevents Vertical Transmission in Brooders.
- Emergence of Advance Fish Vaccine Techniques
- Prevalence of Infectious Diseases
- Growing Aquaculture Industry
- Increasing Number of Artificial Fisheries Across Emerging Regions
- Stringent Environmental Regulations
- Fierce Competitive Pressure
- High Initial Investment
Key Target AudienceFish Vaccine Manufactures, New Entrants and Investors, Fish Vaccine Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
Frequently Asked Questions (FAQ):
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
2. How big is the Fish Vaccine Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.